Virginia
Text replaced here!
For more information, contact NACDS’ Jill McCormack at 717-592-8977.
Text replaced here!
For more information, contact NACDS’ Jill McCormack at 717-592-8977.
Text replaced here!
For more information, contact NACDS’ Mary Staples at 817-442-1155.
The Department of Health Care Services posted the following on the Medi-Cal Rx Web Portal:
Also in California, the Board of Pharmacy posted the agendas for the following committee meetings:
Finally in California, the Board of Pharmacy published the May 2026 issue of "The Script".
For more information, contact NACDS’ Sandra Guckian at 703-774-4801.
On June 2, Gov. Jared Polis (D) signed HB 26-1336, legislation supported by NACDS, that expands access to pharmacy healthcare services and authorizes payment for these services. The bill enables children aged 12 years and older to receive test-and-treat services directly at pharmacies. Additionally, it permits pharmacy technicians, under the supervision of a pharmacist, to perform final product verification and other technical, non-discretionary tasks.
Also in Colorado, the Department of Health Care Policy and Financing (HCPF) posted new information on the federal-level implementation of H.R. 1 because members and providers will be affected by these changes. HCPF updated the FAQs for stakeholders and for members, and created a work requirements screening tool. Also available are overview pages about H.R. 1 on both the Health First Colorado site and the HCPF site.
For more information, contact NACDS’ Mary Staples at 817-442-1155.
The Board of Pharmacy scheduled a Board Meeting for June 11 at 8:30 am EDT.
For more information, contact NACDS’ Leigh Knotts at 803-243-7207.
The Board of Pharmacy posted information related to prescriptive authority for chiropractors holding a clinical nutrition certificate.
For more information, contact NACDS’ Sandra Guckian at 703-774-4801.
The Department of Healthcare and Family Services issued a Provider Notice RE: Rybelsus Tablets to Ozempic Tablets. This change will apply to both the fee-for-service (FFS) program and Managed Care Organizations (MCOs) plans. There are no changes to Ozempic injections.
Novo Nordisk informed the Department of Healthcare and Family Services (HFS) that it will discontinue all strengths of Rybelsus tablets, requiring patients to be transitioned to Ozempic tablets. Beginning in May 2026, shipments of Rybelsus tablets to wholesalers will cease, with existing inventory expected to become limited starting in July 2026.
Please see notice for details. Questions regarding this notice may be directed to the Bureau of Professional and Ancillary Services at 877-782-5565 or the applicable MCO.
For more information, contact NACDS’ Leigh Knotts at 803-243-7207.
The legislature adjourned sine die on June 1.
Also in Louisiana, the Pharmaceutical & Therapeutics (P&T) Committee updated the Preferred Drug List (PDL) that will take effect July 1.
For more information, contact NACDS’ Mary Staples at 817-442-1155.
The Department of Health and Human Services released Bulletin MMP 26-20 announcing that Medicaid and other public programs will reimburse pharmacists for immunizations, lab testing, antiviral treatments and counseling and prescribing of hormonal contraceptives, effective July 1, contingent upon CMS approval. It also outlines the provider enrollment process.
For more information, contact NACDS’ Jill McCormack at 717-592-8977.